Andreas Argyrides
Stock Analyst at Oppenheimer
(4.46)
# 221
Out of 4,829 analysts
101
Total ratings
48.84%
Success rate
23.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IFRX InflaRx | Initiates: Outperform | $6 | $1.67 | +259.28% | 1 | May 8, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | $47 → $15 | $13.74 | +9.17% | 8 | Jan 17, 2025 | |
| ASND Ascendis Pharma | Reiterates: Outperform | $181 | $154.43 | +17.21% | 9 | Nov 15, 2024 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $35 | $13.14 | +166.36% | 1 | Oct 16, 2024 | |
| LRMR Larimar Therapeutics | Initiates: Outperform | $26 | $2.08 | +1,150.00% | 1 | Oct 16, 2024 | |
| RGLS Regulus Therapeutics | Reiterates: Outperform | $7 | $7.87 | -11.05% | 1 | Aug 14, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Outperform | $17 | $0.61 | +2,673.25% | 4 | Aug 2, 2024 | |
| LQDA Liquidia | Initiates: Perform | n/a | $15.75 | - | 6 | Jun 25, 2024 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $104 | $40.18 | +158.84% | 14 | Jun 25, 2024 | |
| CLSD Clearside Biomedical | Initiates: Outperform | $5 | $0.89 | +461.48% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $1.10 | +718.18% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $13.29 | +42.96% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $9 | $2.85 | +215.79% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $17.60 | +64.77% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $7.97 | +163.49% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $36.37 | +515.89% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $25.09 | +127.18% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $0.90 | - | 6 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.99 | +609.44% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $4.81 | +107.90% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.75 | +1,239.05% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $61.37 | +14.06% | 6 | Aug 1, 2023 |
InflaRx
May 8, 2025
Initiates: Outperform
Price Target: $6
Current: $1.67
Upside: +259.28%
Keros Therapeutics
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $13.74
Upside: +9.17%
Ascendis Pharma
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $154.43
Upside: +17.21%
Benitec Biopharma
Oct 16, 2024
Initiates: Outperform
Price Target: $35
Current: $13.14
Upside: +166.36%
Larimar Therapeutics
Oct 16, 2024
Initiates: Outperform
Price Target: $26
Current: $2.08
Upside: +1,150.00%
Regulus Therapeutics
Aug 14, 2024
Reiterates: Outperform
Price Target: $7
Current: $7.87
Upside: -11.05%
Rani Therapeutics Holdings
Aug 2, 2024
Initiates: Outperform
Price Target: $17
Current: $0.61
Upside: +2,673.25%
Liquidia
Jun 25, 2024
Initiates: Perform
Price Target: n/a
Current: $15.75
Upside: -
MoonLake Immunotherapeutics
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $40.18
Upside: +158.84%
Clearside Biomedical
Jun 25, 2024
Initiates: Outperform
Price Target: $5
Current: $0.89
Upside: +461.48%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $1.10
Upside: +718.18%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $13.29
Upside: +42.96%
Mar 7, 2024
Maintains: Outperform
Price Target: $4 → $9
Current: $2.85
Upside: +215.79%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $17.60
Upside: +64.77%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $7.97
Upside: +163.49%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $36.37
Upside: +515.89%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $25.09
Upside: +127.18%
Nov 16, 2023
Upgrades: Outperform
Price Target: n/a
Current: $0.90
Upside: -
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.99
Upside: +609.44%
Oct 10, 2023
Initiates: Outperform
Price Target: $10
Current: $4.81
Upside: +107.90%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.75
Upside: +1,239.05%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $61.37
Upside: +14.06%